Welcome to our dedicated page for Marvel Biosciences news (Ticker: MBCOF), a resource for investors and traders seeking the latest updates and insights on Marvel Biosciences stock.
Marvel Biosciences Corp. (OTCQB: MBCOF) generates news primarily around its pre-clinical drug development programs in neurological and neurodevelopmental disorders. Through its subsidiary Marvel Biotechnology Inc., the company focuses on MB-204, a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline, which targets the adenosine A2A receptor.
News updates for Marvel often highlight preclinical study results and scientific recognition. The company has reported data showing strong preclinical efficacy of MB-204 in models of autism, Rett syndrome and depression, as well as reductions in tau hyperphosphorylation in an acute Alzheimer's disease study. Marvel also announces invitations to present at major scientific meetings, such as the Alzheimer's Association International Conference and the International Rett Syndrome Foundation Scientific Meeting, where it shares findings on MB-204 in Alzheimer's disease, Rett syndrome and autism spectrum disorder.
Investors and followers can also expect regular coverage of Marvel's capital markets activities. The company issues news releases about non-brokered private placements of units, the terms of common share purchase warrants, and any acceleration of warrant expiry dates triggered by trading price thresholds on the TSX Venture Exchange. Additional corporate news includes grants of deferred share units to directors in lieu of cash fees, with details on vesting and settlement conditions.
This news page provides a centralized view of Marvel Biosciences' scientific progress, financing transactions and corporate developments related to MB-204. Readers interested in the evolution of the company’s pre-clinical pipeline and its engagement with the neurology and neurodevelopmental research community can use this feed to follow key milestones and disclosures over time.
Marvel Biosciences (TSXV: MRVL; OTCQB: MBCOF) has extended its collaboration with the iBraiN Institute to test its lead drug MB204 in a pre-clinical model of Rett syndrome, a rare genetic neurological disorder. This follows promising results from earlier tests on an autism model. The study will conduct a head-to-head comparison of MB204 against Trofinetide, the only approved treatment for Rett syndrome. Dr. Julie Le Merrer and Dr. Jerome Becker, lead investigators at the iBraiN Institute, believe modulating the adenosine A2a receptor could improve outcomes. Marvel's CEO Rod Matheson expressed optimism that the ongoing research will lead to significant insights and potential treatments for Rett syndrome.
Marvel Biosciences Corp. (TSXV: MRVL) has closed its non-brokered private placement, raising $500,000 through the issuance of 5,000,000 units at $0.10 per unit. Each unit comprises one common share and one warrant, exercisable at $0.15 per share until July 19, 2026. The company paid $25,200 in finders fees and issued 252,000 finder's warrants. Proceeds will fund pre-clinic experiments on MB-204 in chronic Alzheimer's disease and Autism models, and general working capital. The offering is subject to TSX Venture Exchange approval, with securities having a four-month hold period.
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) highlighted a new research paper published by Dr. David Blum, a member of their scientific advisory board. The study, published in 'Brain', discovered that early increases in adenosine A2A receptor (A2aR) in neurons can result in memory loss in Alzheimer's mouse models, specifically linked to Tau phosphorylation at the AT8 site rather than amyloid plaques. Marvel's lead asset, MB204, an A2aR antagonist, has shown promise in reducing Tau phosphorylation in initial studies. This suggests that MB204 could be a valuable approach in treating Alzheimer's.
Marvel Biosciences, through its subsidiary Marvel Biotechnology, focuses on developing new synthetic derivatives of off-patent drugs to target diseases like Alzheimer's, depression, anxiety, ADHD, cancer, and non-alcoholic steatohepatitis. By repurposing existing drugs, Marvel aims to reduce development time, cost, and risk.
On June 21, 2024, Marvel Biosciences (TSXV: MRVL) announced an update regarding its private placement unit offering. The TSX Venture Exchange (TSXV) has conditionally accepted Marvel's proposed non-brokered private placement, initially announced on May 16, 2024. Additionally, the company has been granted a two-week extension until July 17, 2024, to finalize its documentation related to the offering. This extension provides Marvel more time to complete necessary formalities for the private placement, which aims to raise funds for its ongoing business operations and research initiatives.
Marvel Biosciences announced a proposed non-brokered private placement of up to 10,000,000 units at $0.10 per unit, aiming to raise $1,000,000. Each unit includes one common share and one warrant, allowing purchase at $0.15 per share for two years. A triggering event could accelerate the warrant expiry. Finders may receive a fee up to 7% of the proceeds in cash and finder's warrants. The offering targets accredited investors and is subject to a four-month hold period and TSX Venture Exchange approval. Funds will support pre-clinic experiments on MB-204 for Alzheimer's and Autism models, and cover working capital.
FAQ
What is the current stock price of Marvel Biosciences (MBCOF)?
What is the market cap of Marvel Biosciences (MBCOF)?
